Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Date:8/19/2007

SAN DIEGO, Aug. 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today unaudited financial results for the second quarter and six months ended June 30, 2007. Cadence reported a net loss for the second quarter of 2007 of $14.9 million, or $0.52 per share, compared to a net loss of $6.2 million, or $4.92 per share, in the second quarter of 2006. For the six months ended June 30, 2007, the company reported a net loss of $24.5 million, or $0.86 per share, compared to a net loss of $35.4 million, or $28.50 per share for the six months ended June 30, 2006.

As of June 30, 2007, Cadence held cash and cash equivalents of $66.9 million.

"We remain keenly focused on executing the development programs for our two Phase III product candidates, intravenous acetaminophen and Omigard(TM)," said Ted Schroeder, Cadence's President and Chief Executive Officer. "As a result, we are on track to meet our clinical development and pre-commercialization manufacturing objectives for both product candidates. In particular, we are pleased with the recent execution of a development and supply agreement for IV acetaminophen with Baxter Healthcare, a leading global contract manufacturer, which we believe will position us to meet the anticipated demand for this important product candidate upon commercialization and for several years thereafter."

Financial Results

Total operating expenses for the second quarter of 2007 were $15.7 million, compared to $6.6 million for the second quarter of 2006. The increase in operating expenses was p
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... "In America," the popular news television program that airs ... by legendary film actor James Earl Jones, has announced that ... segment. , Botany is commonly described as the scientific ... a bit more complicated than that. Scientists and other professionals ... from the smallest bacteria known to man to the largest ...
(Date:3/25/2015)... Agnition announced today that it will be featured ... the first time at 7:30 a.m. CST March 31 ... the extremely important role soil microbes perform in crop ... Catalystâ„¢ technology that enhances soil and plant health for ... again on April 28. , A biochemist at Agnition ...
(Date:3/25/2015)... March 25, 2015  S&P Capital IQ (MHFI) ... Stock Report coverage on Abattis Bioceuticals Corp . ... ATT): is a specialty biotechnology company with capabilities ... and marketing proprietary ingredients, bio-similar compounds, patented equipment ... North America . The company seeks ...
(Date:3/25/2015)... London, UK (PRWEB) March 25, 2015 ... of natural ingredients in all forms of food nutrients, ... led to a substantial rise in demand for natural ... astaxanthin have started to ramp up their capacities to ... for both natural and synthetic source astaxanthin (used in ...
Breaking Biology Technology:Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... to Include Screening for Targeted Cancer Drugs ... Human Disease Models -, HOPKINTON, Mass., April ... CALP ) today announced a partnership with Horizon,Discovery ... and,Services, (CDAS) oncology cell line and screening capabilities ...
... ADVENTRX,Pharmaceuticals, Inc. (Amex: ANX ) announced today ... position of vice president of manufacturing.,Mr. Hechavarria will ... operations., "We are pleased to have recruited ... chief executive officer. "He brings experience and,leadership in ...
... includes upfront, milestone and royalty payments on future ... ... 8 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,("Lorus") (TSX: LOR; AMEX: LRP), a ... technologies,for the management of cancer, announced today that its subsidiary GeneSense,Technologies, ...
Cached Biology Technology:Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines 2Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines 3ADVENTRX Appoints Vice President of Manufacturing 2ADVENTRX Appoints Vice President of Manufacturing 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R) 5
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... March 17, 2015  MecklerMedia Corporation (OTCQX: MECK) ... for service robots ever held in ... on May 11-13, 2015 at the Javits Convention ... the event include: Acorn Product Development; Axis NJ; ... Kinova Robotics; Littler; NewBotic Corporation; Neya Systems LLC; ...
(Date:3/12/2015)... 2015 Beta Systems today ... access management (IAM) solution for a fixed price ... System,s new IAM package, customers benefit from the ... multiple IAM implementations across different industries. The new ... as any necessary services and consulting. It spans ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... a cellular trigger that normally regulates replenishment of ... in mice. Removing the abnormal stimulation causes the ... a possible treatment for the lethal, aggressive brain ... Erica L. Jackson, of the University of California, ...
... published by BioMed Central, the open access publisher, received ... in the top 10 of their 2005 Journal Citation ... Factor exceeding 3.00, open access journals are confirmed as ... Central's flagship title covering biology in the post-genomic era, ...
... scientists working at the epicenter of the AIDS epidemic ... virus (HIV) "exhausts" killer T cells that would otherwise ... simply "turn off" fully functional T cells by flipping ... studies, however, the scientists showed that they could reinvigorate ...
Cached Biology News:Possible birthplace of malignant brain tumors identified 2Impressive new Impact Factors for BioMed Central's open-access journals 2How HIV 'exhausts' killer T cells 2How HIV 'exhausts' killer T cells 3How HIV 'exhausts' killer T cells 4
Rabbit polyclonal to SERHL ( Abpromise for all tested applications). entrezGeneID: 94009 SwissProtID: Q9H4I8...
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
TNR-R2...
Biology Products: